Breaking News, Collaborations & Alliances

Adcendo, Duality Biologics to Further Expand First-in-Class ADC Pipeline

Strengthening of strategic option license agreement to cover additional novel ADC targets.

Adcendo ApS, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, expanded its current collaboration with Duality Biologics, a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therapeutics. In January 2023, Adcendo announced an agreement to license Duality’s proprietary DITAC (Duality Immune Toxin Antibody Conjugates) linke...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters